JP5223072B2 - ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物 - Google Patents

ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物 Download PDF

Info

Publication number
JP5223072B2
JP5223072B2 JP2007506335A JP2007506335A JP5223072B2 JP 5223072 B2 JP5223072 B2 JP 5223072B2 JP 2007506335 A JP2007506335 A JP 2007506335A JP 2007506335 A JP2007506335 A JP 2007506335A JP 5223072 B2 JP5223072 B2 JP 5223072B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
antibody
αvβ5 integrin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007506335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007531733A (ja
JP2007531733A5 (https=
Inventor
シェパード、ディーン
アタキリト、アムハ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2007531733A publication Critical patent/JP2007531733A/ja
Publication of JP2007531733A5 publication Critical patent/JP2007531733A5/ja
Application granted granted Critical
Publication of JP5223072B2 publication Critical patent/JP5223072B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2007506335A 2004-04-02 2005-03-30 ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物 Expired - Fee Related JP5223072B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55917504P 2004-04-02 2004-04-02
US60/559,175 2004-04-02
PCT/US2005/011222 WO2005094391A2 (en) 2004-04-02 2005-03-30 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012186169A Division JP5681149B2 (ja) 2004-04-02 2012-08-27 ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2007531733A JP2007531733A (ja) 2007-11-08
JP2007531733A5 JP2007531733A5 (https=) 2008-05-22
JP5223072B2 true JP5223072B2 (ja) 2013-06-26

Family

ID=35064346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007506335A Expired - Fee Related JP5223072B2 (ja) 2004-04-02 2005-03-30 ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物
JP2012186169A Expired - Fee Related JP5681149B2 (ja) 2004-04-02 2012-08-27 ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012186169A Expired - Fee Related JP5681149B2 (ja) 2004-04-02 2012-08-27 ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物

Country Status (14)

Country Link
US (2) US20050226865A1 (https=)
EP (2) EP2394662B1 (https=)
JP (2) JP5223072B2 (https=)
CN (1) CN1964740A (https=)
AU (1) AU2005229015C1 (https=)
CA (1) CA2562038C (https=)
CY (1) CY1114497T1 (https=)
DK (1) DK1734996T3 (https=)
ES (2) ES2671522T3 (https=)
HR (1) HRP20130782T1 (https=)
PL (1) PL1734996T3 (https=)
PT (1) PT1734996E (https=)
RS (1) RS52918B (https=)
WO (1) WO2005094391A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767409C (en) * 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
WO2013181666A2 (en) * 2012-06-01 2013-12-05 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
WO2014144616A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 5 antibodies and uses thereof
HK1219740A1 (zh) * 2013-03-15 2017-04-13 Biogen Ma Inc. 使用抗αVβ5抗体治疗和预防急性肾损伤
US10005838B2 (en) * 2013-07-19 2018-06-26 The Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
MA40536A (fr) * 2014-09-12 2016-03-17 Biogen Ma Inc Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US72500A (en) * 1867-12-24 Improvement in bleaceisg and scouring hemp, flax, aid other fibres
US19037A (en) * 1858-01-05 Washing-machine
US19206A (en) * 1858-01-26 Hydrant
US37889A (en) * 1863-03-10 Mode of
US171271A (en) * 1875-12-21 Improvement in bob-sleds
US139398A (en) * 1873-05-27 Improvement in lamp-extinguishers
US181440A (en) * 1876-08-22 Improvement in steam-boiler furnaces
US77321A (en) * 1868-04-28 Amos bank
US10023A (en) * 1853-09-20 Machine fob sawing sticks eob broom-handles
US18192A (en) * 1857-09-15 And samuel m
US19035A (en) * 1858-01-05 mallary
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5231114A (en) 1990-06-22 1993-07-27 Wakunaga Seiyaku Kabushiki Kaisha Polysulfides compounds and lipid peroxidation inhibitor containing the polysulfide compounds as active ingredient
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5527679A (en) 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6291196B1 (en) * 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
CA2131389A1 (en) 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
HUP9802675A3 (en) * 1995-08-14 2000-09-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
US7053041B1 (en) * 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
EP0915698A4 (en) 1996-05-01 1999-08-11 Lilly Co Eli TREATMENT PROCEDURE FOR VEGF-RELATED DISEASES
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
EE04752B1 (et) * 1997-08-08 2006-12-15 The Regents Of The University Of California Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
EP1140205A2 (en) 1998-12-30 2001-10-10 Edema Clearance, Inc. GENE THERAPY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING Na,K-ATPase
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399581B1 (en) 1999-05-11 2002-06-04 Harbor Branch Oceanographic Institution, Inc. Compound possessing potent thrombin receptor antagonist activity
CA2352957A1 (en) 1999-09-29 2001-04-05 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamides for the treatment of integrin-mediated disorders
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6544982B1 (en) 1999-10-29 2003-04-08 Merck & Co., Inc. Thrombin receptor antagonists
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
US6515023B2 (en) 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
WO2001056607A1 (en) 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US6970452B2 (en) 2000-03-13 2005-11-29 Curitell Communications Inc. Common subscriber managing apparatus and method based on functional modeling of a common subscriber server for use in an ALL-IP network and method therefor
AU2001259078A1 (en) 2000-04-18 2001-10-30 Edema Clearance, Inc. Gene theraphy for pulmonary edema using adenovirus vectors encoding a beta2adrenergic receptor gene
UY26780A1 (es) 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
JP2004513953A (ja) 2000-10-24 2004-05-13 メルク　エンド　カムパニー　インコーポレーテッド ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
EP1393075A4 (en) 2001-04-04 2006-06-14 Allergan Inc METHODS OF SCREENING AND USE OF ANGIOGENESIS INHIBITORS
DE60208186T2 (de) 2001-04-09 2006-08-24 Ortho-Mcneil Pharmaceutical Research Inc. Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen
US20040019206A1 (en) 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
WO2004105757A2 (en) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
RS52918B (sr) 2014-02-28
WO2005094391A3 (en) 2005-12-01
CY1114497T1 (el) 2016-10-05
US7815908B2 (en) 2010-10-19
DK1734996T3 (da) 2013-06-10
EP1734996A2 (en) 2006-12-27
CN1964740A (zh) 2007-05-16
JP2013028611A (ja) 2013-02-07
AU2005229015B2 (en) 2012-08-30
WO2005094391A2 (en) 2005-10-13
HK1098077A1 (en) 2007-07-13
EP1734996B1 (en) 2013-05-22
EP2394662A3 (en) 2012-02-22
EP1734996A4 (en) 2008-09-10
US20090280118A1 (en) 2009-11-12
EP2394662A2 (en) 2011-12-14
HRP20130782T1 (en) 2013-09-30
AU2005229015C1 (en) 2013-01-17
CA2562038C (en) 2017-04-25
US20050226865A1 (en) 2005-10-13
JP2007531733A (ja) 2007-11-08
AU2005229015A1 (en) 2005-10-13
CA2562038A1 (en) 2005-10-13
JP5681149B2 (ja) 2015-03-04
ES2671522T3 (es) 2018-06-06
PT1734996E (pt) 2013-07-18
ES2411965T3 (es) 2013-07-09
EP2394662B1 (en) 2018-03-21
PL1734996T3 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
JP5681149B2 (ja) ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物
DK1734997T3 (en) Natalizumab for use in the treatment of diseases requiring steroid treatment
JP6021959B2 (ja) 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用
JP6277127B2 (ja) インスリン様成長因子１による細胞の活性化を阻害するための方法
CN101500592A (zh) 控制组织因子信号转导特异性的组合物和方法
US10087252B2 (en) Methods and compositions for treating and preventing disease associated with αvβ5 integrin
AU2012216372B2 (en) Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
US20220298255A1 (en) E-cadherin activating antibodies and uses thereof
US20080254043A1 (en) Drug For Treating Ischemic Disease
HK1098077B (en) Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
ME02086B (me) Postupci i smeše za lečenje i prevenciju bolesti koje su povezane sa alfa v beta 5 integrinom

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110614

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130212

R150 Certificate of patent or registration of utility model

Ref document number: 5223072

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160322

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees